Purpose: A review of treat-and-extend regimens (TERs) with intravitreal anti–vascular
endothelial growth factor agents in retinal diseases. Methods: There is a lack of consensus …

Retinal Vein Occlusion Review : The Asia-Pacific Journal of Ophthalmology Retinal Vein
Occlusion Review : The Asia-Pacific Journal of Ophthalmology Log in or Register Get new issue …

The high prevalence of cardiovascular disease particularly in the elderly population is
associated with retinal vascular disease. Retinal vein occlusions represent severe …

Importance The comparative clinical effectiveness of ranibizumab, aflibercept, and
bevacizumab for the management of macular edema due to central retinal vein occlusion …

Background Intravitreal anti–vascular endothelial growth factor (VEGF) therapy is now
considered the gold standard for the treatment of various retinal disorders. As therapy has …

Anti-vascular endothelial growth factors (anti-VEGF) have become the most common
treatment modality for many retinal diseases. These include neovascular age-related …

Retinal occlusive diseases are common diseases that can lead to visual impairment. Retinal
artery occlusion and retinal vein occlusion are included in the clinical entity, but they have …

Placental growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF)
family. Upon binding to VEGF-and neuropilin-receptor sub-types, PlGF modulates a range of …

Retinal vein occlusion (RVO)-including central RVO, branch RVO, and hemicentral and
hemispheric RVO—is the second most common vascular cause of visual loss, surpassed …

Introduction: Anti-vascular endothelial growth factor (VEGF) therapy has become the most
commonly used treatment for macular edema secondary to retinal vein occlusion (RVO) …